Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
Paul D. Brown(Mayo Clinic), Deborah Watkins Bruner(Emory University), David Roberge(Centre Hospitalier de l’Université de Montréal), Deepak Khuntia(Mills Peninsula Health Services), Christina Meyers(The University of Texas Health Science Center at Houston), Minesh P. Mehta(Columbia University), Sherry Fox(Bon Secours Health System), Nadia N. Laack(Mayo Clinic), Vivek S. Kavadi(The US Oncology Network), Søren M. Bentzen(University of Wisconsin–Madison), John H. Suh(Cleveland Clinic), Ali Choucair(Norton Healthcare), Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center), S. Pugh(RTOG Foundation)
Cited by 942
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k